Viyash Scientific (NSE:VIYASH) Cyclically Adjusted Revenue per Share: ₹65.57 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:VIYASH Viyash Scientific Ltd NSE:VIYASH
68 GF Score
Price ₹265.15
GF Value ₹174.87
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Viyash Scientific Cyclically Adjusted Revenue per Share?

Viyash Scientific NSE:VIYASH +0.23% 68 Cyclically Adjusted Revenue per Share is ₹65.57 as of Mar. 2026. GuruFocus rates NSE:VIYASH with a GF Score™ of 68/100 and a GF Value™ of ₹174.87 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Viyash Scientific's adjusted revenue per share for the three months ended in Mar. 2026 was ₹20.655. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹65.57 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Viyash Scientific's average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Viyash Scientific was 8.10% per year. The lowest was 6.60% per year. And the median was 7.60% per year.

As of today (2026-07-22), Viyash Scientific's current stock price is ₹265.15. Viyash Scientific's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹65.57. Viyash Scientific's Cyclically Adjusted PS Ratio of today is 4.04.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Viyash Scientific was 6.58. The lowest was 1.21. And the median was 2.94.


Viyash Scientific  (NSE:VIYASH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Viyash Scientific's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=265.15/65.57
=4.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Viyash Scientific was 6.58. The lowest was 1.21. And the median was 2.94.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Viyash Scientific Cyclically Adjusted Revenue per Share Related Terms


Viyash Scientific Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Viyash Scientific's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viyash Scientific Cyclically Adjusted Revenue per Share Chart

Viyash Scientific Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.54 52.06 54.60 60.53 65.57

Viyash Scientific Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.53 61.56 62.88 64.34 65.57

NSE:VIYASH vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Viyash Scientific's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viyash Scientific Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viyash Scientific's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Viyash Scientific's Cyclically Adjusted PS Ratio falls into.


NSE:VIYASH
68GF Score
Viyash Scientific Ltd NSE:VIYASH
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viyash Scientific Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Viyash Scientific's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=20.655/164.2724*164.2724
=20.655

Current CPI (Mar. 2026) = 164.2724.

Viyash Scientific Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 6.914 105.961 10.719
201609 9.666 105.961 14.985
201612 8.315 105.196 12.985
201703 7.681 105.196 11.995
201706 7.750 107.109 11.886
201709 8.107 109.021 12.216
201712 9.273 109.404 13.924
201803 9.324 109.786 13.951
201806 9.320 111.317 13.754
201809 10.328 115.142 14.735
201812 11.008 115.142 15.705
201903 10.857 118.202 15.089
201906 11.405 120.880 15.499
201909 11.749 123.175 15.669
201912 12.934 126.235 16.831
202003 11.373 124.705 14.982
202006 11.888 127.000 15.377
202009 14.132 130.118 17.841
202012 14.496 130.889 18.193
202103 13.995 131.771 17.447
202106 14.685 134.084 17.991
202109 13.973 135.847 16.897
202112 14.225 138.161 16.913
202203 15.120 138.822 17.892
202206 13.684 142.347 15.792
202209 13.504 144.661 15.335
202212 15.234 145.763 17.168
202303 14.280 146.865 15.973
202306 13.386 150.280 14.632
202309 14.037 151.492 15.221
202312 13.143 152.924 14.118
202403 13.992 153.035 15.019
202406 15.584 155.789 16.433
202409 14.125 157.882 14.697
202412 30.975 158.323 32.139
202503 30.906 157.552 32.224
202506 17.274 159.755 17.762
202509 16.683 162.289 16.887
202512 19.428 163.281 19.546
202603 20.655 164.272 20.655

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹65.57 mean?
Viyash Scientific (NSE:VIYASH) has a Cyclically Adjusted Revenue per Share of ₹65.57 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Viyash Scientific and its competitors.
Is Viyash Scientific's Cyclically Adjusted Revenue per Share too high?
Viyash Scientific's current Cyclically Adjusted Revenue per Share is ₹65.57. Overall, Viyash Scientific has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viyash Scientific's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Viyash Scientific's Cyclically Adjusted Revenue per Share of ₹65.57 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Viyash Scientific and its competitors. Viyash Scientific's current Cyclically Adjusted Revenue per Share is ₹65.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viyash Scientific stock overvalued right now?
Based on GuruFocus' analysis, Viyash Scientific (NSE:VIYASH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹174.87, compared to a current price of ₹265.15 — trading 51.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹65.57. Viyash Scientific's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Viyash Scientific (NSE:VIYASH), the current Cyclically Adjusted Revenue per Share is ₹65.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Viyash Scientific (NSE:VIYASH) Overvalued in 2026?

Based on GuruFocus' analysis, Viyash Scientific stock appears to be overvalued. The current stock price of ₹265.15 is trading 51.6% above its estimated GF Value™ of ₹174.87. GuruFocus considers Viyash Scientific to be Significantly Overvalued.

Key valuation signals for NSE:VIYASH:

  • Cyclically Adjusted Revenue per Share: ₹65.57
  • GF Value™: ₹174.87 vs. price of ₹265.15 (51.6% above fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the NSE:VIYASH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Viyash Scientific Business Description

Other Exchanges 512529:India
Address Road No.6, Kakatiya Hills, 3rd Floor, Srivalli’s Corporate, Plot No. 290, Guttala Begumpet, Jubilee Hills, Madhapur, Survey number 33 34P to 39, Hyderabad, KA, IND, 500033
Viyash Scientific Ltd is a pharmaceutical company with activities spanning formulations, active pharmaceutical ingredients (APIs), and intermediates. It is focused on research and development infrastructure for APIs and formulations. Its product portfolio spans several therapeutic areas, including ARV, cardiovascular, central nervous system, analgesics, antibiotics, antihistamines, diabetes, gastrointestinal, anticoagulants, and oncology.
68GF Score

Get the complete analysis for NSE:VIYASH

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹265.15
Price
₹174.87
GF Value